Mycoplasma infections in sheep, goats and yaks

Mycoplasmas were isolated from yak calves in Mongolia, the 1st experience worldwide with this species. They were also isolated from pathologically affected sheep and goat lambs. The disease was experimentally reproduced in yak calves as well as in sheep and goat lambs. Clinical manifestations were identical with those recordable from animals with spontaneous outbreak of the disease. This had been for the 1 time ever that a therapy was tested on animals with mycoplasmosis, using water with addition of oligodynamic silver. Something between 95 and 100% of all patients were clinically cured. The experimental vaccine involved was found to offer protection against mycoplasmosis to sheep and goat lambs. Damage association with mycoplasmosis was found to occur 1st in liver, spleen, and lymph nodes and to be subsequently proliferated to lung and other organs. Respiratory mycoplasmosis is the common definition used at present but is not in conformity with the pathological processes involved, as the major role is played by liver damage. Mycoplasmosis in these 3 species, therefore, should better be named mycoplasmosis bovi hepatica.     

Experimental infections of goats with Mycoplasma mycoides subspecies mycoides, LC type

In five experiments 29 goats were infected experimentally by five different routes with a strain of Mycoplasma mycoides subspecies mycoides, LC type, isolated from a contagious caprine pleuropneumonia-like outbreak on a farm in northern Sweden. All the goats were colonised except those inoculated subcutaneously with small doses. In its pattern of pathogenicity this strain was similar to other experimentally tested strains except that peroral infection in kids produced no clinical signs. A 'contact' goat was also colonised but the clinical signs seen in it were probably due to a concomitant infection with Pasteurella haemolytica.     

Mycoplasma bovis infections in cattle

Mycoplasma bovis is a pathogen causing respiratory disease, otitis media, arthritis, mastitis, and a variety of other diseases in cattle worldwide. It is increasingly recognized by the veterinary and livestock communities as having an important impact on the health, welfare, and productivity of dairy and beef cattle. M. bovis diseases can be difficult to diagnose and control because of inconsistent disease expression and response to treatments and vaccines, and large gaps in our understanding of the epidemiology and pathophysiology of these diseases. There are limited data on which to base evidence-based decisions for treatment and control, and the literature contains differing clinical biases and opinions. This document is intended for veterinarians dealing with cattle and is focused on the cattle production systems of North America. The goal of the consensus statement panel was to encourage an evidence-based approach to M. bovis problems. The scientific literature was critically reviewed, including peer-reviewed journal articles and reviews obtained by database searches using the terms "Mycoplasma bovis" or "mycoplasma + cattle." Where other data were lacking, conference proceedings were reviewed as a source of expert opinion.     

Ostertagia ostertagi infections in angora goats

Angora goats grazing on a paddock contaminated with Ostertagia ostertagi and O. circumcincta were found to have infections consisting of equal numbers of both species. Subsequently, goats were infected with O. ostertagi larvae of bovine origin. The infection became patent by day 28 and egg counts reached a plateau about 7 weeks after infection. Worm numbers did not decline during the 12 weeks of the experiment. It was concluded that Angora goats are suitable hosts for O. ostertagi.     

Experimental infections of Ostertagia ostertagi in goats

In order to determine the usefulness of the goat as a model host for Ostertagia ostertagi, a series of experiments was conducted in which young goats and calves were experimentally infected with L3 of calf-source and goat-source isolates. The goat-source isolate was derived from a continuous passage of the bovine parasite in goats. Patent infections resulted in 73 out of 86 inoculated goats (85%). The largest number of patent infections was observed when inoculation consisted of a single dose of goat-source larvae. Percentage establishment of infection was generally low in goats inoculated with either larval source. Time taken to achieve patency in goats was frequently within the range normal for cattle infections, but was often extended (21-67 days). With the exception of the generally higher level of establishment of goat- or calf-source isolates in calves and the low frequency of the vulval flap in adult female worms established in goats, little difference was observed in percentage establishment or worm population characteristics of the two isolates in goats.     

Mycoplasma infections in small ruminants.

Mycoplasmas have complex mechanisms of antigenic variation that allow them to evade the immune system. These organisms cause a variety of clinical syndromes that can have a significant economic effect on small ruminant production. The syndromes range from acute septicemia and death to chronic infection resulting in decreased production. Recent research findings have shed light on the means by which these organisms evade the host immune response and cause or contribute to the development of disease in the host. This article provides a review of the pathogenesis, clinical signs, and treatment options for common disease syndromes involving Mycoplasma spp. in small ruminants.     

防治支原体感染的生物安全措施与疫苗接种

Janet M Bradbury博士在泰国曼谷举行的世界家禽学会第八届亚太家禽论坛（2007年3月）上作了一场题为“支原体感染的检测和流行病学与当前研究状况”的报告。她明确表示,对家禽进行支原体感染检测仍是有必要的。     

Control of Mycoplasma hyopneumoniae infections in pigs

Mycoplasma hyopneumoniae, the primary pathogen of enzootic pneumonia, occurs worldwide and causes major economic losses to the pig industry. The organism adheres to and damages the ciliated epithelium of the respiratory tract. Affected pigs show chronic coughing, are more susceptible to other respiratory infections and have a reduced performance. Control of the disease can be accomplished in a number of ways. First, management practices and housing conditions in the herd should be optimized. These include all-in/all-out production, limiting factors that may destabilize herd immunity, maintaining optimal stocking densities, prevention of other respiratory diseases, and optimal housing and climatic conditions. Strategic medication with antimicrobials active against M. hyopneumoniae and, preferably, also against major secondary bacteria may be useful during periods when the pigs are at risk for respiratory disease. Finally, commercial bacterins are widely used to control M. hyopneumoniae infections. The main effects of vaccination include less clinical symptoms, lung lesions and medication use, and improved performance. However, bacterins provide only partial protection and do not prevent colonization of the organism. Different vaccination strategies (timing of vaccination, vaccination of sows, vaccination combined with antimicrobial medication) can be used, depending on the type of herd, the production system and management practices, the infection pattern and the preferences of the pig producer. Research on new vaccines is actively occurring, including aerosol and feed-based vaccines as well as subunit and DNA vaccines. Eradication of the infection at herd level based on age-segregation and medication is possible, but there is a permanent risk for re-infections.     

“猪地方性肺炎及其防治控制”专栏四：猪肺炎支原体的防治措施

猪肺支原体是猪地方性肺炎的主要病原体,其普遍存在于世界各地,会给养猪业造成巨大的经济损失。此病原体感染猪后通常黏附于猪呼吸道纤毛上皮,并会造成纤毛上皮的损伤。猪感染后主要表现为慢性咳嗽症状、容易发生其他呼吸道感染和生产性能下降。该病的控制可通过多种措施实现,首先应该完善管理措施,改善畜舍饲养环境,这包括实行全出/全进的饲养方式、减少会破坏群体免疫水平的因素、维持最佳的饲养密度、防止其他呼吸道疾病的感染,以及提供最佳的畜舍及环境条件。其次,当猪群处于呼吸道疾病感染的威胁之下时,战略性使用能够有效地预防猪肺炎支原体和最好还能预防大多数继发感染细菌的药物对预防本病非常有效。最后,商用疫苗已被广泛地用来控制猪肺炎支原体感染,接种疫苗的优点在于其能够减少临床症状、减轻肺脏损伤、减少药物的使用和提高猪群的生产性能。但是,疫苗仅能提供部分保护作用,并且不能防止病原体在猪体内的定殖。因此,应根据猪群的种类、猪场的生产系统和管理体制、感染的类型及猪农的喜好选择不同的免疫策略（免疫时机、母猪免疫、免疫接种再结合抗菌素治疗）。新疫苗正在紧锣密鼓的研究之中,如气雾苗、通过饲料接种的疫苗以及亚单位苗和DNA疫苗。按年龄进行隔离饲养和药物治疗在猪群水平上根除猪肺炎支原体感染是可能的,但该病复发的威胁将永久存在。     

猪肺炎支原体的防治措施

猪肺支原体是猪地方性肺炎的主要病原体,其普遍存在于世界各地,会给养猪业造成巨大的经济损失.此病原体感染猪后通常黏附于猪呼吸道纤毛上皮,并会造成纤毛上皮的损伤.猪感染后主要表现为慢性咳嗽症状、容易发生其他呼吸道感染和生产性能下降.该病的控制可通过多种措施实现.首先应该完善管理措施.改善畜舍饲养环境,这包括实行全出/全进的饲养方式、减少会破坏群体免疫水平的因素、维持最佳的饲养密度、防止其他呼吸道疾病的感染,以及提供最佳的畜舍及环境条件.其次,当猪群处于呼吸道疾病感染的威胁之下时,战略性使用能够有效地预防猪肺炎支原体和最好还能预防大多数继发感染细菌的药物对预防本病非常有效.最后,商用疫苗已被广泛地用来控制猪肺炎支原体感染,接种疲苗的优点在于其能够减少临床症状、减轻肺脏损伤、减少药物的使用和提高猪群的生产性能.但是,疫苗仅能提供部分保护作用,并且不能防止病原体在猪体内的定殖.因此,应根据猪群的种类、猪场的生产系统和管理体制、感染的类型及猪农的喜好选择不同的免疫策略(免疫时机、母猪免疫、免疫接种再结合抗菌素治疗).新疫苗正在紧锣密鼓的研究之中.如气雾苗、通过饲料接种的疫苗以及亚单位苗和DNA疫苗.按年龄进行隔离饲养和药物治疗在猪群水平上根除猪肺炎支原体感染是可能的,但该病复发的威胁将永久存在.